Growth Metrics

Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$31.8 million.

  • Tonix Pharmaceuticals Holding's Income from Continuing Operations fell 10102.29% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.7 million, marking a year-over-year increase of 3109.61%. This contributed to the annual value of -$136.7 million for FY2024, which is 3920.11% down from last year.
  • Tonix Pharmaceuticals Holding's Income from Continuing Operations amounted to -$31.8 million in Q3 2025, which was down 10102.29% from -$27.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Income from Continuing Operations registered a high of -$15.8 million during Q3 2024, and its lowest value of -$77.3 million during Q2 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Income from Continuing Operations averaged around -$29.7 million, with its median value being -$27.3 million (2023).
  • The largest annual percentage gain for Tonix Pharmaceuticals Holding's Income from Continuing Operations in the last 5 years was 6462.14% (2025), contrasted with its biggest fall of 10102.29% (2025).
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Income from Continuing Operations stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then crashed by 41.62% to -$31.8 million in 2025.
  • Its Income from Continuing Operations was -$31.8 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$16.1 million in Q1 2025.